

HPS Investment Partners CLO (UK) LLP
MIFIDPRU8 Disclosure
Financial year end 31 December 2023

1. Introduction

- 1.1 HPS Investment Partners CLO (UK) LLP (the “**Firm**”) is authorised and regulated by the Financial Conduct Authority (“**FCA**”) of the United Kingdom and is a “MIFIDPRU investment firm” as defined in the FCA Rules. The Firm is a non-SNI firm for the purposes of the rules in the Prudential sourcebook for MiFID Investment Firms (“**MIFIDPRU**”). This document sets out certain disclosures the Firm is required to make under Chapter 8 of MIFIDPRU.
- 1.2 The Firm is a limited liability partnership and its members are HPS Investment Partners (UK) I, Ltd. and HPS Investment Partners (UK) II, Ltd. which are both wholly owned by HPS Investment Partners, LLC (“**HPS LLC**” and together with its affiliates the “**HPS Group**”). HPS LLC is an investment advisor registered with the U.S. Securities and Exchange Commission and manages investments in various strategies across the capital structure, including syndicated leveraged loans, high yield bonds, privately negotiated senior secured debt and mezzanine investments, asset-based leasing and private equity.
- 1.3 The Firm provides collateral management services to collateralised loan obligations (each a “**CLO**”) and invests in and hold retention interests in the CLOs it manages. In providing these services to the CLOs, the Firm manages portfolios of debt instruments comprising secured senior obligations, unsecured senior obligations, second lien loans, mezzanine obligations and high yield bonds. The Firm receives certain administrative, management and advisory services from HPS Investment Partners (UK) LLP (“**HPSUK**”), also a member of the HPS Group. The Firm does not employ any staff itself but utilises the services of staff employed by HPSUK under these arrangements.
- 1.4 The Firm is part of a consolidation group for prudential regulation purposes. However, in accordance with MIFIDPRU 8.1.7 R, the Firm is providing these disclosures on a solo basis only.

2. Significant changes since last disclosure period

- 2.1 There have been no significant changes to the information disclosed since the Firm’s last disclosure period.

3. Governance arrangements

- 3.1 The Firm, as a MIFIDPRU Investment Firm, is subject to the organisational requirements in 4.3A.1 R of the Senior Management Arrangements, Systems and Controls Sourcebook of the FCA Handbook (“**SYSC**”). The Firm’s governing body is its operating committee (the “**Management Body**”). The Management Body meets at least quarterly to discuss significant matters affecting the Firm and to make strategic decisions. Under the Firm’s governance arrangements, the Management Body has overall responsibility for the business and conduct of the Firm and approves and oversees implementation of the Firm’s strategic objectives, risk strategy and internal governance. All members of the Management Body are required to commit sufficient time to ensure that they can perform their functions within the Firm and to act with honesty, integrity and independence of mind to effectively assess and challenge decisions where necessary and to effectively oversee and monitor management decision-making.
- 3.2 The Firm ensures, as required under SYSC 4.3A.1 R, that the Management Body defines, oversees and is accountable for the implementation of governance arrangements that ensure effective and prudent management of the Firm, including the segregation of duties in the organisation and the

mitigation of conflicts of interest, and in a manner that promotes the integrity of the market and the interests of the Firm's clients.

3.3 In order to comply with the requirement in SYSC 4.3A.1 R, the Firm has procedures in place to ensure that members of the Management Body are selected based primarily on the following criteria:

- reputation within the market
- the possession of the necessary knowledge, skills and experience to perform the relevant duties
- whether their addition will complement the Management Body's collective knowledge, skills and experience in relation to the Firm's activities, including the main risks it faces
- diversity of viewpoints, backgrounds, experiences, and other demographics.

3.4 In accordance with SYSC 4.3A.10 R, the Firm maintains a policy for promoting diversity on the Management Body. The Policy recognises the benefits of having a diverse management body and aims to maintain or increase the diversity of the Management Body in the belief that a desirable longer term goal of maintaining an effective Management Body to support the attainment of the Firm's strategic objectives and its sustainable development. As the Firm is a relatively small firm with a relatively small Management Body it has chosen not to set specific targets in relation to the diversity of its Management Body at this time.

3.5 The Firm is required to disclose the number of directorships each member of the Management Body holds, broken down into executive and non-executive directorships. As at the date of this disclosure, the members of the Management Body do not hold any other executive or non-executive directorships, excluding entities which do not pursue a predominantly commercial objective, other entities within the HPS Group and HPS portfolio companies.

3.6 The Firm is not required to establish a risk committee, and has not established such a committee.

4. **Risk Management objectives and policies**

4.1 The Firm's Management Body is committed to managing the Firm's risks. The Management Body establishes the Firm's overall risk appetite by identifying the risks it will be exposed to in pursuing its business objectives and considering whether it is prepared to accept such risks, coordinating as necessary with the HPS Group as a whole.

4.2 "Risk appetite" is the level of risk that the Firm considers is acceptable for a given risk or group of risks. Controls are implemented by the Firm and strategies revised, with the aim of bringing operational and reputational risk within an acceptable range. The aim is for the business to grow and prosper but to achieve that growth without putting the Firm's business or a material amount of its capital at risk.

4.3 In pursuing its business objectives, the activities of the Firm will give rise to certain risks which carry a potential for harm. Below we have set out a summary of the harm that could potentially be caused as a result of certain categories of risks related to the Firm's (i) Own Funds requirement; (ii) requirements around its Concentration risk; and (iii) requirements around its Liquidity. We have also set out a summary of the strategies and processes used to manage each of these categories of risk.

Risks Related to the Firm's Own Funds Requirement

- 4.4 The Firm considers the material harms that could result from the ongoing operation of the Firm's business in its ICARA process. The risks identified include the following:

Cybersecurity risk. Cybersecurity is a generic term used to describe the technology, processes and practices designed to protect networks, systems, computers, programs and data from both intentional cyber-attacks and hacking by other computer users as well as unintentional damage or interruption that, in either case, can result in damage and disruption to hardware and software systems, loss or corruption of data and/or misappropriation of confidential information. A breach in cybersecurity could cause harm directly and also expose the Firm to civil liability as well as regulatory inquiry and/or action. The HPS Group has implemented various measures to manage risks associated with cybersecurity breaches, including establishing a business continuity plan and systems designed to detect and prevent cyber-attacks and training of staff.

Key person risk. The Firm's business is dependent on the skill and expertise of its staff. Although the Firm believes that its success is not dependent upon any particular individual, the unavailability of particular members of staff could have a material adverse effect on the Firm. The Firm aims to mitigate these risks via contractual protections, competitive compensation and incentive programmes and regular review of non-pecuniary aspects of employment.

Price risk: Price risk is the risk of a decline in the value of a security or a portfolio. The Firm is exposed to CLO securities price risk with respect to the CLO securities it holds, the prices of which can be highly volatile, because investments held are marked to market through earnings. The prices of these instruments are influenced by numerous factors, including interest rates, currency rates, default rates, governmental policies and political and economic events (both domestic and global). Moreover, political or economic crisis, or other events may occur that can be highly disruptive to the markets. In addition, governmental authorities from time to time intervene (directly and by regulation), which intervention may adversely affect the performance and investment activities of the Firm. The Firm's investment is also subject to the risk of a temporary or permanent failure of the exchanges and other markets on which its investments may trade. Sustained market turmoil and periods of heightened market volatility make it more difficult to produce positive trading results, and there can be no assurance that strategies employed will be successful in such markets. Furthermore, the Firm holds interests in the first loss class of the securities issued by the CLO. As such there is a risk which could have a material impact on the Firm. In managing each CLO, the Firm seeks to diversify the portfolio of such CLO subject to the investment mandate of such CLO. The Firm believes that such diversification mitigates the price risk of the Firm's investment in such CLO.

Conduct risk. The Firm is exposed to the risk that a member of staff engages in conduct which adversely affects the Firm. Misconduct by an employee of, or contractor to, the Firm or one of its affiliates, or even unsubstantiated allegations of such misconduct, could result in direct financial and/or reputational harm to the Firm and/or the HPS Group. The Firm mitigates this risk through its governance framework, maintaining robust compliance and monitoring policies, training of employees and effective reporting and whistleblowing procedures.

The Firm has not considered it necessary to ascribe additional capital for these risks.

Concentration Risk

- 4.5 The Firm has cash deposits with a small number of financial institutions, exposing the Firm to risk in the event of any such institution's insolvency. The Firm aims to mitigate this risk by considering the credit rating of counterparties with whom it deposits cash.

Liquidity

4.6 The Firm has identified the following risks of harm arising from its strategy which relate to the Firm's Liquidity obligations:

- Assets cannot be converted to liquid assets within a reasonable time, including under stressed conditions.
- Liquid assets are not denominated in the same currency as expected outflows.
- The Firm's financing arrangements are or become concentrated in terms of counterparties, maturity, any security provided, products, currencies and geographical location.

The Firm manages and mitigates the risks of harm identified above and other liquidity risks through various strategies and processes including active monitoring of cash balances, tracking of expenses and escalation of any issues identified.

5. **Own Funds and Own Funds Requirement**

Own Funds

5.1 The Firm is subject to the disclosure requirements stipulated in MIFIDPRU 8.4.1 R. As such, the tables below set out:

- A. details of common equity tier 1 items, additional tier 1 items, tier 2 items, and the applicable filters and deductions applied in order to calculate the own funds of the Firm (i.e. a composition of regulatory own funds)
- B. a reconciliation of the Firm's composition of regulatory own funds with the capital in the balance sheet in the audited financial statements of the Firm
- C. a description of the main features of the common equity tier 1 instruments, additional tier 1 instruments and tier 2 instruments issued by the Firm.

Please see the tables below which set out these disclosures.

A. Composition of regulatory own funds			
	Item	Amount (GBP thousands)	Source based on reference numbers/letters of the balance sheet in the audited financial statements
1	OWN FUNDS	45,302	
2	TIER 1 CAPITAL	45,302	
3	COMMON EQUITY TIER 1 CAPITAL	45,302	
4	Fully paid up capital instruments	53,657	Page 9, Members' capital
5	Share premium		
6	Retained earnings		
7	Accumulated other comprehensive income		
8	Other reserves	(8,355)	Page 9, Other reserves
9	Adjustments to CET1 due to prudential filters		
10	Other funds		
11	(-)TOTAL DEDUCTIONS FROM COMMON EQUITY TIER 1		
19	CET1: Other capital elements, deductions and adjustments		
20	ADDITIONAL TIER 1 CAPITAL	0	
21	Fully paid up, directly issued capital instruments		
22	Share premium		
23	(-) TOTAL DEDUCTIONS FROM ADDITIONAL TIER 1		
24	Additional Tier 1: Other capital elements, deductions and adjustments		
25	TIER 2 CAPITAL	0	
26	Fully paid up, directly issued capital instruments		
27	Share premium		
28	(-) TOTAL DEDUCTIONS FROM TIER 2		
29	Tier 2: Other capital elements, deductions and adjustments		

B. Own funds: reconciliation of regulatory own funds to balance sheet in the audited financial statements				
		Balance sheet as in published/audited financial statements (EUR thousands)	Under regulatory scope of consolidation	Cross-reference to template OF1
		As at period end	As at period end	
Assets - Breakdown by asset classes according to the balance sheet in the audited financial statements				
1	Investments	209,637		
2	Debtors	22,393		
3	Cash at bank and in hand	7,976		
	Total Assets	240,006		
Liabilities - Breakdown by liability classes according to the balance sheet in the audited financial statements				
1	Creditors: Amounts falling due within one year	8,142		
2	Borrowings	179,558		
	Total Liabilities	187,700		
Shareholders' Equity				
1	Members' capital	61,954		4
2	Other reserves	(9,647)		8
	Total Shareholders' equity	52,307		3

C. Own funds: main features of own Instruments issued by the Firm
<p>The CET 1 instruments issued by the firm consist of LLP members' capital. The instruments have been issued on an <i>ad hoc</i> basis as and when new LLP members have been admitted or when the Firm has required additional capital. The LLP members' capital does not have a nominal value. Its value reflects the amount paid in by the relevant member. Under the terms of the Firm's LLP Agreement, the LLP members' capital is non-convertible and perpetual (it does not have a maturity date), carries no right to dividends, coupon or other forms of income (instead, LLP members may, at the discretion of the Firm be awarded a share in the profits of the Firm at the end of the financial year) and is subject to restrictions on withdrawal in accordance with the requirements of MIFIDPRU 3.3.17 R.</p>

Own Funds Requirements

5.2 The below table relates to the Firm's own funds requirements under MIFIDRU 4.3.

K-Factor Requirement (calculated by the Firm in accordance with MIFIDPRU 4.6) (GBP thousands)	The Firm's K-Factor Requirement is: 781	The Firm's K-Factor Requirement can be further broken down as follows:
		the sum of: - the K-AUM requirement; - the K-CMH requirement; and - the K-ASA requirement, which is: 781
		the sum of: - the K-COH requirement; and - the K-DTF requirement. which is: 0
		the sum of: - the K-NPR requirement; - the K-CMG requirement; - the K-TCD requirement; and - K-CON requirement, which is: 0
Fixed Overheads Requirement (calculated by the Firm in accordance with MIFIDPRU 4.5) (GBP thousands)	The Firm's Fixed Overheads Requirement is: 1,372	

5.3 As part of its ICARA process, the Firm assesses the adequacy of its own funds in accordance with the overall financial adequacy rule in MIFIDPRU 7.4.7 R.

5.4 In particular, the Firm assesses the own funds it requires to:

- address any potential harms it has identified which it has not been able to mitigate
- address any residual harms remaining after mitigation
- ensure an orderly wind down of its business

5.5 As the Firm is not an SNI firm, it is required to use its K-factor requirement as a starting point for determining the appropriate amount of own funds to cover risks of harm to the business as a going concern, to the extent that such risks have not or cannot be mitigated.

5.6 The Firm assesses whether and to what extent a K-factor requirement covers each risk of harm identified during the ICARA process on a going concern basis (to the extent the risk of harm is not or cannot be adequately mitigated).

5.7 For this purpose, each risk of harm that is not adequately mitigated is mapped to the corresponding K-factor requirement. To the extent that the applicable K-factor requirement is insufficient to cover the post mitigation risk of harm or to the extent that there is no applicable K-factor requirement, the Firm will calculate a suitable amount of additional capital.

5.8 As part of its ICARA, the Firm also assesses the level of own funds that it would need in order to effect an orderly wind down, taking into account any additional risks of harm it identifies and whether the Firm's fixed overheads requirement adequately covers such risks.

6. **Remuneration policy and practices**

Qualitative disclosures

6.1 Although the Firm does not employ any staff itself, it utilises the services of staff employed by HPSUK and this section describes the remuneration practices applicable to such employees.

6.2 HPSUK aims to ensure that individual employees' remuneration is consistent with and promotes sound and effective risk management and does not encourage excessive risk-taking while supporting the Firm's business objectives. HPSUK's Management Body has adopted remuneration policies and practices it believes to be in line with the rules and guidance laid down by the FCA and SYSC 19G (the "**MIFIDPRU Remuneration Code**") and is responsible for the implementation of such policies and practices. The Firm has not established a remuneration committee, pursuant to its classification as a non-SNI firm subject to the standard remuneration requirements. For the purposes of SYSC 19G.5.1R the Firm has identified the members of its Management Body as material risk takers ("**MRTs**").

6.3 HPSUK's remuneration practices include an assessment of an individual's performance, based on both quantitative criteria (for example, financial performance of the individual and their business unit) and qualitative criteria (for example, holistic assessment of general adherence to certain policies and procedures). The qualitative criteria used may include, among others, consideration of the employee's contribution to the overall control of downside risk and volatility in the investment portfolios and identification of attractive return opportunities, and variable remuneration may be adjusted accordingly.

6.4 HPSUK seeks to achieve its objectives by offering a balanced total compensation program comprising a mix of fixed compensation, including base salary and other benefits, and variable compensation in the form of cash payments. In addition, certain employees may be awarded incentive plans which entitle the recipient to a fixed percentage of carried interest earned by the HPS Group on the realisation of certain investments by funds managed by entities in the HPS Group, subject to the governing documents of the relevant funds and their associated carry vehicles. Variable compensation is based on the financial performance of HPSUK and the HPS Group as a whole, as well as the individual's own performance, taking in to account the individual's annual performance review (including peer review) and non-financial criteria, such as compliance with HPSUK's policies and procedures and risk management framework. HPSUK aims to ensure that the fixed and variable components of total remuneration are appropriately balanced and the fixed component represents a sufficiently high proportion of the total remuneration to enable the operation of a fully flexible policy on variable remuneration, including the possibility of paying no variable remuneration component.

6.5 The amount HPSUK makes available for variable remuneration is subject to adjustments for current and future risks and the cost of the capital and liquidity required as determined by HPSUK. This includes risks relating to the achievement of the HPS Group's business strategy and its financial performance. The Firm may apply malus (adjustment) and clawback (recovery) provisions to an MRT's variable remuneration in circumstances where it is warranted due to the MRT's conduct in accordance with the MIFIDPRU Remuneration Code requirements.

6.6 In exceptional and justified circumstances, HPSUK may award guaranteed variable compensation, granted as part of a contractual obligation. Guarantees for MRTs will be subject to appropriate level

of approvals, limited to the first year of employment only and are awarded to attract a new employee.

- 6.7 In certain circumstances and at the HPSUK’s absolute discretion, severance payments may be made. In such circumstances, severance pay is determined on a case-by-case basis and involves input from the Firm’s control functions as appropriate. Any payments related to early termination of an MRT employment contract will reflect performance achieved over time and will be designed in a way which does not reward failure or misconduct.

Quantitative disclosures

- 6.8 The total number of MRTs identified by the Firm under SYSC 19G.5 as at 31 December 2022 was 4.
- 6.9 Remuneration paid or awarded for the financial year ended 31 December 2022 comprised fixed remuneration (salaries, allowances and director fees) and variable remuneration. The following tables show aggregate quantitative remuneration information individuals identified as “Senior Management” and “Other Staff” allocated to the Firm, as required under MIFIDPRU 8.6.8R (4) and (5)(a) and (b).

<i>Fixed and Variable Remuneration</i>	
<i>Senior Management</i>	
Total remuneration awarded to Senior Management	£2,176,556
Fixed remuneration awarded to Senior Management	£311,466
Variable remuneration awarded to Senior Management	£1,865,090
<i>Other Staff</i>	
Total remuneration awarded to Other Staff	£2,474,868
Fixed remuneration awarded to Other Staff	£1,296,612
Variable remuneration awarded to Other Staff	£1,178,256

<i>Guaranteed Variable Remuneration</i>	
Number of Senior Management that received guaranteed variable remuneration awards	0
Total amount of guaranteed variable remuneration awards made to Senior Management	-

<i>Severance Payments</i>	
Number of Senior Management that received severance payment awards	0

Total amount of severance payment awards made to Senior Management	-
Highest severance payment awarded to an individual classified as Senior Management	-